Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

Watts, GF; Chan, DC; Dent, R; Somaratne, R; Wasserman, SM; Scott, R; Burrows, S; Barrett, PHR

Watts, GF (reprint author), Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Lipid Disorders Clin,Dept Cardiol, GPO Box X2213, Perth, WA 6847, Australia.

CIRCULATION, 2017; 135 (4): 338

Abstract

BACKGROUND: Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprot......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索